Do peroxisome proliferation receptor-γ antagonists have clinical potential as combined antiobesity and antidiabetic drugs?

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 713-716

  Doggrell, Sheila ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diabetes; Mouse models; Obesity; SR 202

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CD36 ANTIGEN; DEXAMETHASONE; DICLOFENAC; DIMETHYL ALPHA(DIMETHOXYPHOSPHINYL) 4 CHLOROBENZYL PHOSPHATE; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; LG 100341; LG 100641; LIPOPROTEIN LIPASE; MESSENGER RNA; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR; ROSIGLITAZONE; STEROID RECEPTOR COACTIVATOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BODY FAT; BODY WEIGHT; CORRELATION FUNCTION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FEEDING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; TISSUE DIFFERENTIATION; WILD TYPE;

EID: 0037396860     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.713     Document Type: Review

References (13)

1. RIEUSSET J, TOURI F, MICHALIK L et al.: A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol (2002) 16:2628-2644.
2. MORI Y, MURAKAWA Y, OKADA K et al.: Effect of troglitazone on body fat distribution in Type 2 diabetic patients. Diabetes Care (1999) 22:908-912.
3. HIROSE H, KAWAI T, YAMAMOTO Y et al.: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with Type 2 diabetes. Metabolism (2002) 51:314-317.
4. KERSEN S, DESVERGNE B, WAHLI W: Roles of PPARs in health and disease. Nature (2000) 405:421-424.
5. DEEB SS, FAJA L, NEMOTO M et al.: A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284-287.
6. KUBOTA N, TERAUCHI Y, MIKI H et al.: PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell (1999) 4:597-609.
7. OBERFIELD JL, COLLINS JL, HOLMES CP et al.: A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA (1999) 96:6102-6106.
8. WRIGHT MH, CLISH CB, MIKAMI T et al.: A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. (2000) 275:1873-1877.
9. MUKHERJEE R, HOENER PA, JOW L et al.: A selective peroxisome proliferator-activated receptor γ (PPARγ) modulator bocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. (2000) 14:1425-1433.
10. CAMP HS, CHAUDRY A, LEFF T: A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology (2001) 142:3207-3213.
11. YAMAUCHI T, WAKI H, KAMON J et al.: Inhibition of RXR and PPARγ ameliorates diet-induced obesity and Type 2 diabetes. J. Clin. Invest. 108:1001-1013.
12. FRÜHBECK G, GÓMEZ-AMBROSI, MURUZÁBAL FJ, BURRELL MA: The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 280:E827-E847.
13. ADAMSON DJ, FREW D, TATOUD R, WOLF CR, PALMER CN: Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling. Mol. Pharmacol. (2002) 61:7-12.